Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
cache
Home
cache
Next Post
Previous Post
cache
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in
TSC1
and
TSC2
using the Foundation Medicine genomic database
Aadi Bioscience Closes $23 Million in Series A Funding
Mohammad Hirmand, MD
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Biomarker Analysis From AMPECT Correlating Response to
nab
-Sirolimus in PEComa With
TSC1
and
TSC2
Inactivating Alterations
Read More
Neil Desai, PhD
cache
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.